Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership.
View / Open Files
Authors
Stephens, RJ
Whiting, C
Cowan, K
James Lind Alliance Mesothelioma Priority Setting Partnership Steering Committee
Publication Date
2015-08Journal Title
Lung Cancer
ISSN
0169-5002
Publisher
Elsevier BV
Volume
89
Issue
2
Pages
175-180
Language
eng
Type
Article
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Stephens, R., Whiting, C., Cowan, K., & James Lind Alliance Mesothelioma Priority Setting Partnership Steering Committee. (2015). Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership.. Lung Cancer, 89 (2), 175-180. https://doi.org/10.1016/j.lungcan.2015.05.021
Abstract
BACKGROUND: In the UK, despite the import and use of all forms of asbestos being banned more than 15 years ago, the incidence of mesothelioma continues to rise. Mesothelioma is almost invariably fatal, and more research is required, not only to find more effective treatments, but also to achieve an earlier diagnosis and improve palliative care. Following a debate in the House of Lords in July 2013, a package of measures was agreed, which included a James Lind Alliance Priority Setting Partnership, funded by the National Institute for Health Research. The partnership brought together patients, carers, health professionals and support organisations to agree the top 10 research priorities relating to the diagnosis, treatment and care of patients with mesothelioma. METHODS: Following the established James Lind Alliance priority setting process, mesothelioma patients, current and bereaved carers, and health professionals were surveyed to elicit their concerns regarding diagnosis, treatment and care. Research questions were generated from the survey responses, and following checks that the questions were currently unanswered, an interim prioritisation survey was conducted to identify a shortlist of questions to take to a final consensus meeting. FINDINGS: Four hundred and fifty-three initial surveys were returned, which were refined into 52 unique unanswered research questions. The interim prioritisation survey was completed by 202 responders, and the top 30 questions were taken to a final meeting where mesothelioma patients, carers, and health professionals prioritised all the questions, and reached a consensus on the top 10. INTERPRETATION: The top 10 questions cover a wide portfolio of research (including assessing the value of immunotherapy, individualised chemotherapy, second-line treatment and immediate chemotherapy, monitoring patients with pleural thickening, defining the management of ascites in peritoneal mesothelioma, and optimising follow-up strategy). This list is an invaluable resource, which should be used to inform the prioritisation and funding of future mesothelioma research.
Keywords
James Lind Alliance Mesothelioma Priority Setting Partnership Steering Committee, Humans, Mesothelioma, Lung Neoplasms, Research, Mesothelioma, Malignant
Identifiers
External DOI: https://doi.org/10.1016/j.lungcan.2015.05.021
This record's URL: https://www.repository.cam.ac.uk/handle/1810/326869
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk